Mode
Text Size
Log in / Sign up

Insulin administration associated with lower 28-day mortality in non-diabetic sepsis patientsInsulin Might Help Sepsis Patients Survive Longer

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider insulin may be associated with lower sepsis mortality but longer hospital stays in non-diabetic patients.

This retrospective cohort study used the MIMIC-IV database to analyze 11,289 non-diabetic patients with sepsis. The intervention was insulin administration, with a comparator of untreated (no insulin). The primary outcome was 28-day mortality, and secondary outcomes were ICU and hospital length of stay, with a 28-day follow-up.

The main results showed a reduced mortality rate in the insulin group, with a hazard ratio of 0.63-0.67 (p < 0.001). However, the insulin group had a longer median ICU length of stay (5 days vs. 4 days, p < 0.001) and a longer hospital length of stay (12 days vs. 10 days, p < 0.001). Absolute numbers for these outcomes were not reported.

Safety and tolerability data, including adverse events, serious adverse events, and discontinuations, were not reported. Key limitations include the observational design, which cannot prove causality, and the need for further research to elucidate the underlying mechanism and validate these findings.

The practice relevance suggests insulin therapy may improve survival but does not shorten hospitalization. The study evaluates an association; causality is not explicitly claimed. Given the observational nature, clinicians should interpret these findings cautiously.

The Hidden Danger of Sepsis

Imagine a patient fighting a severe infection in the ICU. Their body is under attack. Doctors work hard to save them. But sometimes, the patient still passes away. This happens even when doctors do everything right.

Sepsis is a life-threatening response to an infection. It happens when the body's immune system goes into overdrive. This reaction can damage organs and lead to death. Sadly, many people get sepsis every year. It affects anyone, but it is especially dangerous for those who are already sick.

Current treatments focus on fighting the infection and supporting organs. Doctors give antibiotics and fluids. But mortality rates remain high. We need better ways to help these patients survive.

Scientists have long believed that insulin is only for people with diabetes. They thought giving it to others was unnecessary. But new data suggests this old rule might be wrong.

The Surprising Shift

For years, doctors avoided giving insulin to non-diabetic patients. They worried about low blood sugar. Now, a new study changes this view.

But here's the twist. The study looked at 11,289 critically ill patients. Most did not have diabetes. Yet, those who received insulin had a better chance of living past 28 days.

Think of your cells like houses. Glucose is the energy they need to function. In sepsis, the body releases stress hormones. These hormones lock the doors to the houses. Energy gets stuck outside the cells.

Insulin acts like a master key. It unlocks the doors. This allows glucose to enter the cells. The cells get the fuel they need to fight the infection. This simple action might stop the body from shutting down.

Researchers used a large database called MIMIC-IV. It contains records from real hospital stays. They found 11,289 patients with sepsis who did not have diabetes.

Of these, 1,172 patients received insulin. The team carefully matched these patients with others who did not get insulin. This ensured both groups were similar in age and health. They tracked who survived and who did not within 28 days.

The results were clear. Patients who got insulin were much less likely to die. The chance of death dropped significantly. This held true for all groups studied.

However, there was a trade-off. Patients on insulin stayed in the ICU longer. Their average stay was five days instead of four. They also stayed in the hospital longer overall.

This doesn't mean this treatment is available yet.

The longer stay might be because doctors monitored these patients more closely. Or, the treatment might have stabilized them for a longer recovery. More research is needed to understand this delay.

Doctors are cautious about new findings. They want to see if results hold up in real life. This study is a strong start. It suggests insulin could be a vital tool in the ICU.

It fits into a bigger picture of treating sepsis. We are moving toward personalized care. Every patient is different. What works for one might not work for another. This study helps guide that decision.

If you know someone with sepsis, talk to their doctor. Ask about their blood sugar levels. Insulin might be part of their care plan.

Do not try to give insulin at home. This is a hospital treatment. It requires careful monitoring. Always follow your medical team's advice. They know the best path for your specific situation.

This study has limits. It looked at past records. It did not control every variable. Also, the study was done on data from one source. We need more trials to confirm these results.

The link between insulin and survival is promising. But we do not fully understand why it works. Scientists are still studying the biology behind this.

More research is coming. Large clinical trials will test insulin in diverse populations. We need to know if it works everywhere.

Regulatory bodies will review the data. If results are strong, guidelines may change. Doctors might start using insulin more often for sepsis. This could save more lives in the future.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
ObjectiveTo evaluate the association between insulin administration and 28-day mortality in non-diabetic patients with sepsis.MethodsA retrospective analysis of 11,289 critically ill patients with sepsis in the MIMIC-IV database was conducted. Propensity score matching (PSM) was employed to balance baseline characteristics between the insulin-treated and untreated cohorts. The primary outcome was 28-day mortality; secondary outcome measures included intensive care unit (ICU) and hospital length of stay (LOS). The association between insulin use and mortality was evaluated via Cox regression analysis, and survival was estimated using Kaplan-Meier curves and log-rank tests.ResultsOf the 11,289 non-diabetic patients meeting the inclusion criteria, 1,172 (10.4%) received insulin. After PSM, the final analysis included 2,960 patients (782 in the insulin group and 2,178 in the control group). Baseline characteristics were well-balanced, with standardized mean differences (SMDs) close to zero. Insulin use was significantly associated with a reduced 28-day mortality rate (hazard ratio [HR] 0.63-0.67, p < 0.001), a finding that remained consistent across all subgroups. However, patients receiving insulin therapy had a longer median ICU LOS (5 days vs. 4 days, p < 0.001) and a more extended hospital LOS (12 days vs. 10 days, p < 0.001).ConclusionInsulin therapy may improve the survival rate among non-diabetic patients with sepsis but does not shorten the duration of hospitalization. Further research is warranted to elucidate the underlying mechanism and validate these findings.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.